Tempus AI (TEM) EV/EBITDA: History & Chart

Tempus AI, Inc. (TEM)TEMTempus AI, Inc.

About Tempus AI, Inc.

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Chicago, IL

3,800 employees

www.tempus.com

Healthcare / Medical - Healthcare Information Services

Sector: Healthcare
Industry: Medical - Healthcare Information Services
CEO: Eric Lefkofsky

View full financials

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Tempus AI, Inc. (TEM)	$7.51B	N/A	N/A	N/A	N/A
Oscar Health, Inc. (OSCR)vs ›	$7.35B	123.70x	97.32x	52.28x	52.28x
Hims & Hers Health, Inc. (HIMS)vs ›	$6.75B	73.67x	66.05x	319.02x	319.02x
Bio-Rad Laboratories, Inc. (BIO)vs ›	$8.55B	21.36x	21.04x	19.55x	21.80x
Henry Schein, Inc. (HSIC)vs ›	$9.64B	12.84x	11.45x	11.86x	11.66x
Universal Health Services, Inc. (UHS)vs ›	$9.97B	5.48x	6.83x	8.19x	8.21x
Walgreens Boots Alliance, Inc. (WBA)vs ›	$10.37B	N/A	32.35x	25.45x	22.17x
Molina Healthcare, Inc. (MOH)vs ›	$10.41B	19.83x	7.60x	9.03x	10.48x
Charles River Laboratories International, Inc. (CRL)vs ›	$10.80B	16.93x	17.64x	16.04x	17.45x
Bio-Techne Corporation (TECH)vs ›	$11.21B	44.54x	40.98x	35.49x	38.57x

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

Tempus AI, Inc. (TEM)

$7.51B

N/A

Oscar Health, Inc. (OSCR)vs ›

$7.35B

123.70x

97.32x

52.28x

Hims & Hers Health, Inc. (HIMS)vs ›

$6.75B

73.67x

66.05x

319.02x

Bio-Rad Laboratories, Inc. (BIO)vs ›

$8.55B

21.36x

21.04x

19.55x

21.80x

Henry Schein, Inc. (HSIC)vs ›

$9.64B

12.84x

11.45x

11.86x

11.66x

Universal Health Services, Inc. (UHS)vs ›

$9.97B

5.48x

6.83x

8.19x

8.21x

Walgreens Boots Alliance, Inc. (WBA)vs ›

$10.37B

N/A

32.35x

25.45x

22.17x

Molina Healthcare, Inc. (MOH)vs ›

$10.41B

19.83x

7.60x

9.03x

10.48x

Charles River Laboratories International, Inc. (CRL)vs ›

$10.80B

16.93x

17.64x

16.04x

17.45x

Bio-Techne Corporation (TECH)vs ›

$11.21B

44.54x

40.98x

35.49x

38.57x

EV/EBITDA Ratio: N/A

TEM EV/EBITDA Ratio Metrics

TEM Competitors' EV/EBITDA Ratio

EV/EBITDA Ratio Formula & Definition

Related Metrics